IP Library Granted Patent US 10,045,976
Granted Patent B2
US 10,045,976 · App. 15/366,678 · Granted Aug 14, 2018

Nicotine-containing liquid formulations and uses thereof

Inventors: Rolando Fusco (Montreal, CA); Leonardo Calderone (Montreal, CA)
Assignee: EURO-PHARM INTERNATIONAL CANADA INC.
A61K31/465A61K9/006A61K47/10A61K47/26
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,045,976
App. No.
15/366,678
Granted
Aug 14, 2018
Kind
B2
Abstract

Nicotine liquid formulations and their use in therapy, for instance, in nicotine replacement therapy are described. More specifically, the technology relates to liquid nicotine formulations comprising nicotine, one or more diol and/or triol, and a sugar alcohol, which may be used as sprays for administration through the oral cavity, such as the palate.

Claims (21)

1. A liquid formulation comprising nicotine, at least one lower alkyl diol and/or triol, a sugar alcohol and water, wherein the liquid formulation is free of ethanol, wherein the weight ratio of the sugar alcohol to nicotine is from about 1:1 to about 3:1.

2. The liquid formulation of claim 1 , wherein the content in nicotine in the formulation ranges from about 0.2 wt % to about 2.5 wt %.

3. The liquid formulation of claim 2 , wherein the content in nicotine in the formulation ranges from about 0.4 wt % to about 1.5 wt %.

4. The liquid formulation of claim 1 , wherein the sugar alcohol is selected from maltitol, sorbitol, xylitol, erythritol, and isomalt.

5. The liquid formulation of claim 4 , wherein the sugar alcohol is xylitol.

6. The liquid formulation of claim 1 , wherein the content in sugar alcohol in the formulation ranges from about 0.5 w % to about 10 wt %.

7. The liquid formulation of claim 6 , wherein the content in sugar alcohol in the formulation ranges from about 0.8 w % to about 5 wt %.

8. The liquid formulation of claim 1 , wherein the weight ratio of sugar alcohol to nicotine is about 2:1.

9. The liquid formulation of claim 1 , wherein said formulation comprises two or more lower alkyl diol, lower alkyl triol, or a combination thereof.

10. The liquid formulation of claim 1 , wherein the lower alkyl diol and/or triol is selected from ethylene glycol, propylene glycol, and glycerol.

11. The liquid formulation of claim 1 , wherein the total content in lower alkyl diol and/or triol in the formulation ranges from about 45 wt % to about 85 wt %.

12. The liquid formulation of claim 11 , wherein the total content in lower alkyl diol and/or triol in the formulation ranges from about 55 wt % to about 75 wt %.

13. The liquid formulation of claim 1 , wherein the lower alkyl diol and/or triol comprises propylene glycol and glycerol.

14. The liquid formulation of claim 13 , wherein the lower alkyl diol and/or triol comprises propylene glycol and glycerol in a weight ratio of about 4:6 to about 8:2.

15. The liquid formulation of claim 1 , further comprising a flavoring agent.

16. The liquid formulation of claim 15 , wherein the content in the flavoring agent in the formulation is from about 3 wt % to about 20 wt %.

17. The liquid formulation of claim 1 , wherein the content in water in the formulation is 30 wt % or lower.

18. The liquid formulation of claim 15 , wherein the flavoring agent is selected from mint, grape, coffee, orange, and a combination thereof.

19. The liquid formulation of claim 17 , wherein the content in water in the formulation is about 10 wt % to about 25 wt %.

20. Method for treating, reducing, or alleviating at least one tobacco withdrawal symptom in a subject in need thereof, comprising administering to said subject an effective amount of a liquid formulation as defined in claim 1 .

21. The method of claim 20 , wherein said liquid formulation is administered to the mouth cavity, for instance, in the form of an oral spray.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 29, 2018
From: EURO-PHARM INTERNATIONAL CANADA INC.
To: EURO-PHARM INTERNATIONAL CANADA INC.; NIC-HIT INTERNATIONAL INC.
Reel/Frame 047616/0723 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 1, 2017
From: FUSCO, ROLANDO; CALDERONE, LEONARDO
To: EURO-PHARM INTERNATIONAL CANADA INC.
Reel/Frame 041426/0990 →
Priority Claims (1)
CA 2914089 · Dec 3, 2015 · national
Continuity (1)
Related Publication 20170157107A1 · Jun 8, 2017
Cited By (23)
US 12,213,510 US 12,274,779 US 12,295,412 US 12,310,394 US 12,310,959 US 12,318,479 US 12,342,847 US 12,382,982 US 12,433,321 US 12,433,322 US 12,439,949 US 12,439,952 US 12,484,617 US 12,491,250 US 12,496,276 US 12,520,867 US 12,550,928 US 12,564,552 US 12,599,159 US 12,599,160 US 12,667,539 US 12,691,059 US 12,714,701